Cardiology in Review最新文献

Impact of Body Mass Index on Cardiac Arrest Outcomes: A Systematic Review and Meta-Analysis. 体重指数对心脏骤停结果的影响:一项系统回顾和荟萃分析。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2025-11-01 Epub Date: 2023-11-30 DOI: 10.1097/CRD.0000000000000633

Wangmin Xie, Jie Zhou, Huifei Zhou

{"title":"Impact of Body Mass Index on Cardiac Arrest Outcomes: A Systematic Review and Meta-Analysis.","authors":"Wangmin Xie, Jie Zhou, Huifei Zhou","doi":"10.1097/CRD.0000000000000633","DOIUrl":"10.1097/CRD.0000000000000633","url":null,"abstract":"The influence of an individual's body mass index (BMI) on cardiac arrest outcomes remains uncertain. The aim of this study is to evaluate the impact of BMI categories (underweight, normal BMI, overweight, and obese) on mortality and neurological outcomes in patients experiencing cardiac arrest. We comprehensively searched standard electronic databases (PubMed, EMBASE, and Scopus) for relevant observational studies published in peer-reviewed journals written in English. We calculated pooled effect estimates using random-effects models and reported them as odds ratios (ORs) with 95% confidence intervals (CIs). We included 20 studies in our meta-analysis. Individuals with normal BMIs and those who were underweight had similar risks of in-hospital mortality (OR, 1.20; 95% CI, 0.90-1.60), mortality within 6 months of discharge (OR, 0.92; 95% CI, 0.59-1.42), mortality after the 1-year follow-up (OR, 2.42; 95% CI, 0.96-6.08), and odds of favorable neurological outcomes at hospital discharge (OR, 0.86; 95% CI, 0.53-1.39) and at the 6-month follow-up (OR, 0.73; 95% CI, 0.47-1.13). The risks of in-hospital mortality and mortality within 6 months of discharge in overweight and obese individuals were similar to those in individuals with normal BMIs. However, overweight (OR, 0.57; 95% CI, 0.35-0.92) and obese individuals (OR, 0.67; 95% CI, 0.51-0.89) had lower risks of mortality after their 1-year follow-ups. For overweight and obese subjects, the reduced risk of mortality after the 1 year of follow-up was noted only for those with in-hospital cardiac arrest and not for those with out-of-hospital cardiac arrest. The odds of favorable neurological outcomes in both overweight and obese individuals were similar to those with normal BMIs. BMI does not significantly impact short-term mortality or neurological outcomes. Overweight and obese individuals appear to have a lower risk of long-term mortality, but this differed by the place of arrest and needs to be confirmed by others.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"483-493"},"PeriodicalIF":2.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138458084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Coronavirus Disease 2019 (COVID-19) in Heart Transplant Recipients and Anti-SARS-CoV-2 Monoclonal Antibodies: Experience, Lessons Learnt, and Future Challenges. 2019年心脏移植受者冠状病毒病（COVID-19）与抗SARS-CoV-2单克隆抗体：经验、教训和未来挑战。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2025-11-01 Epub Date: 2024-02-08 DOI: 10.1097/CRD.0000000000000640

Rohan Kapur, Kenji Okumura, Suguru Ohira, Ameesh Isath, Aditya Gandhi, Marina Keller, Rajat Nog, Alan Gass, David Spielvogel, Steven Lansman, Abhay Dhand

{"title":"Coronavirus Disease 2019 (COVID-19) in Heart Transplant Recipients and Anti-SARS-CoV-2 Monoclonal Antibodies: Experience, Lessons Learnt, and Future Challenges.","authors":"Rohan Kapur, Kenji Okumura, Suguru Ohira, Ameesh Isath, Aditya Gandhi, Marina Keller, Rajat Nog, Alan Gass, David Spielvogel, Steven Lansman, Abhay Dhand","doi":"10.1097/CRD.0000000000000640","DOIUrl":"10.1097/CRD.0000000000000640","url":null,"abstract":"Solid organ transplant recipients (SOTRs), including heart transplant (HT) recipients, infected with Coronavirus disease 2019 (COVID-19) are at higher risk of hospitalization, mechanical ventilation, or death when compared with general population. Advances in diagnosis and treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have reduced COVID-19-related mortality rates from ~30% in the early pandemic to <3% in 2022 among HT recipients. We performed a retrospective chart review including adult HT recipients at Westchester Medical Center from January 1, 2020 to December 10, 2022, who received anti-SARS-CoV-2 monoclonal antibodies (mAbs) for treatment of mild-to-moderate COVID-19, and those who received tixagevimab/cilgavimab for preexposure prophylaxis. Additionally, a comprehensive review of the literature involving SOTRs who received mAbs for COVID-19 was conducted. In this largest single-center study in this population, 42 adult HT recipients received casirivimab/imdevimab (36%), sotrovimab (31%), or bebtelovimab (29%) for treatment of mild-to-moderate COVID-19. Among these recipients, no infusion-associated adverse effects, progression of disease, COVID-19-associated hospitalizations, or death were noted. Preexposure prophylaxis with tixagevimab/cilgavimab was given to 63 HT recipients in a dedicated infusion center (40%), inpatient setting (33%), or at time of annual heart biopsy (27%). No immediate adverse events were noted. There were 11 breakthrough infections, all mild. Overall, the data suggests that HT recipients receiving mAbs have reduced rates of hospitalization, need for intensive care unit care, or death. Use of anti-SARS-CoV-2 mAbs in SOTRs is resource intensive and requires a programmatic team approach for optimal administration and to minimize any risk of disparities in their use.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"522-530"},"PeriodicalIF":2.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139706191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Low-Dose Colchicine for the Prevention of Cardiovascular Events After Acute Coronary Syndrome. 小剂量秋水仙碱用于预防急性冠状动脉综合征后的心血管事件。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2025-11-01 Epub Date: 2024-01-08 DOI: 10.1097/CRD.0000000000000650

Priyanka Gera, David Haner Wasserstein, William H Frishman, Wilbert S Aronow

{"title":"Low-Dose Colchicine for the Prevention of Cardiovascular Events After Acute Coronary Syndrome.","authors":"Priyanka Gera, David Haner Wasserstein, William H Frishman, Wilbert S Aronow","doi":"10.1097/CRD.0000000000000650","DOIUrl":"10.1097/CRD.0000000000000650","url":null,"abstract":"Colchicine, an established anti-inflammatory drug, is examined for its potential in mitigating adverse cardiovascular events following acute coronary syndrome (ACS). ACS, primarily triggered by plaque rupture and subsequent thrombosis, is a critical cardiovascular condition. Colchicine's mechanism of action involves inhibiting microtubule activity, leading to immobilization of white blood cells and reducing inflammation. Clinical data from studies, including low-dose colchicine for secondary prevention of cardiovascular disease two and colchicine cardiovascular outcomes trial, support its efficacy in reducing major cardiovascular events post-ACS, though some studies report varying results. Colchicine can cause transient gastrointestinal side effects and is prescribed with caution in patients with certain medical conditions. The recent FDA approval of a low dose of colchicine reiterates its benefit in reducing cardiovascular risk. The cost-effectiveness of colchicine products (0.5 and 0.6 mg doses) are compared, suggesting the generic 0.6 mg dose of colchicine to be an alternative to branded forms of the drug.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"517-521"},"PeriodicalIF":2.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139377226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

You Cannot Manage What You Do Not Measure: Advances in Global Stroke Interventions and the Role of the Mechanical Thrombectomy Access Score. 你不能管理你没有测量：全球卒中干预的进展和机械取栓的作用。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2025-11-01 Epub Date: 2025-04-04 DOI: 10.1097/CRD.0000000000000914

Fawaz Al-Mufti, Zaid Najdawi, Mohamed Elfil, Ankita Jain, Eris Spirollari, Ariel Sacknovitz, Hazem S Ghaith, Priyank Khandelwal, Victor C Urrutia, Nabeel A Herial, Pankajavalli Ramakrishnan, Gabor Toth, Mohammad El-Ghanem, Krishna Amuluru, Viktor Szeder, Jonathan R Crowe, Karol Budohoski, Zurab Nadareishvili, Kaustubh Limaye, Fazeel Siddiqui, Hamza Shaikh, Nishita Singh, Hesham Masoud, Sushanth R Aroor, Shashvat M Desai, Santiago Ortega-Gutierrez, Tareq Kass-Hout, Dileep R Yavagal, Kaiz S Asif

{"title":"You Cannot Manage What You Do Not Measure: Advances in Global Stroke Interventions and the Role of the Mechanical Thrombectomy Access Score.","authors":"Fawaz Al-Mufti, Zaid Najdawi, Mohamed Elfil, Ankita Jain, Eris Spirollari, Ariel Sacknovitz, Hazem S Ghaith, Priyank Khandelwal, Victor C Urrutia, Nabeel A Herial, Pankajavalli Ramakrishnan, Gabor Toth, Mohammad El-Ghanem, Krishna Amuluru, Viktor Szeder, Jonathan R Crowe, Karol Budohoski, Zurab Nadareishvili, Kaustubh Limaye, Fazeel Siddiqui, Hamza Shaikh, Nishita Singh, Hesham Masoud, Sushanth R Aroor, Shashvat M Desai, Santiago Ortega-Gutierrez, Tareq Kass-Hout, Dileep R Yavagal, Kaiz S Asif","doi":"10.1097/CRD.0000000000000914","DOIUrl":"10.1097/CRD.0000000000000914","url":null,"abstract":"Global disparities in stroke care, particularly in acute interventions like mechanical thrombectomy (MT), remain profound, with the Mechanical Thombectomy Global Access for Stroke study reporting a median global MT access of just 2.79%. Furthermore, the low- and middle-income countries (LMICs) have been recognized to be disproportionately burdened in this regard as compared with high-income countries. These observed inequities in stroke care impact not only clinical outcomes but also economic productivity and social systems. Recent advancements, such as TeleStroke networks, Mobile Stroke Units, and artificial intelligence-powered tools, have the potential to bridge these gaps. The Mechanical Thrombectomy Access Score (MTAS) offers a novel standardized approach to quantifying barriers to MT access and guiding targeted interventions to mitigate such obstacles. This review explores how MTAS enables the integration of these advancements into global stroke care systems, addressing inequities and optimizing outcomes. Emphasizing the importance of measuring access to manage inequities, we propose strategies to refine and validate MTAS while advocating for systemic investments to enhance global stroke care.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"467-469"},"PeriodicalIF":2.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Palliative Care in Cardiovascular Disease. 姑息治疗在心血管疾病中的作用。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2025-11-01 Epub Date: 2025-10-03 DOI: 10.1097/CRD.0000000000000634

John Arthur McClung, William H Frishman, Wilbert S Aronow

引用次数: 0

New Oral PCSK9 Inhibitor: "MK-0616". 新型口服 PCSK9 抑制剂："MK-0616"。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2025-11-01 Epub Date: 2024-01-29 DOI: 10.1097/CRD.0000000000000655

Zoya Siddiqui, William Frishman

{"title":"New Oral PCSK9 Inhibitor: \"MK-0616\".","authors":"Zoya Siddiqui, William Frishman","doi":"10.1097/CRD.0000000000000655","DOIUrl":"10.1097/CRD.0000000000000655","url":null,"abstract":"MK-0616, a novel oral macrocyclic peptide inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), represents a significant advancement in the treatment of hypercholesterolemia. Unlike current PCSK9 inhibitors, which are injectable monoclonal antibodies and siRNA molecules, MK-0616 offers a patient-friendly alternative. The development of MK-0616 involved innovative synthetic chemistry and in vitro mRNA display technology. This cutting-edge approach led to the creation of an orally administered peptide with the ability to cover a larger portion of PCSK9 compared to smaller, linear peptides. Phase 1 and 2b clinical trials have demonstrated MK-0616's safety, efficacy, and pharmacokinetics. These trials indicate the drug's dose-dependent systemic absorption and long half-life. Notably, MK-0616 has exhibited comparable low-density lipoprotein cholesterol-lowering effects to currently available PCSK9 inhibitors, all while maintaining good tolerability in diverse patient populations, including those concurrently on statin therapy. As MK-0616 advances to Phase 3 trials, its lipid-lowering potential for heterozygous familial hypercholesterolemia and its impact on reducing the time to adverse cardiac events will be evaluated in a broad and diverse population, including underrepresented groups. The results achieved so far are promising for individuals with hypercholesterolemia, as they offer a potential solution for effectively lowering low-density lipoprotein cholesterol in patients on statin therapy and mitigating the risk of cardiovascular events. Ongoing research and monitoring will be critical to establish its long-term safety and efficacy, but MK-0616 may emerge as a valuable addition to the array of lipid-lowering therapies available to patients.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"573-577"},"PeriodicalIF":2.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139575221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Thrombotic and Vascular Complications of Oral Contraceptives. 口服避孕药的血栓和血管并发症。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2025-11-01 Epub Date: 2024-01-17 DOI: 10.1097/CRD.0000000000000643

Stephen Windisch, William H Frishman

{"title":"Thrombotic and Vascular Complications of Oral Contraceptives.","authors":"Stephen Windisch, William H Frishman","doi":"10.1097/CRD.0000000000000643","DOIUrl":"10.1097/CRD.0000000000000643","url":null,"abstract":"The oral contraceptive pill is the most commonly used form of reversible contraception, as it has significantly grown in popularity in recent years. The 2 types of oral contraceptive pills are combination oral contraceptives, which contain estrogen and progesterone, and progestin-only pills. Both have failure rates of approximately 7.2-9% with typical use and are safe for most patients. However, several thrombotic and vascular complications have been found to be associated with the usage of oral contraceptive pills, most notably being an increase in blood pressure and thrombosis. Although these complications do not typically affect young, healthy females, they merit concern for patients with a history of hypertension or thrombosis or patients with preexisting risk factors for these conditions. Overall, progestin-only pills are the safer option regarding these complications. Additionally, a complete summary of the medical eligibility criteria for contraceptive use has been created and is regularly updated by the Centers for Disease Control and Prevention. This chart summarizes the recommendations for contraception use by patients with a variety of preexisting conditions or risk factors.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"502-508"},"PeriodicalIF":2.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139478103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SGLT2 Inhibition in Heart Failure: Clues to Cardiac Effects? 心力衰竭中的 SGLT2 抑制：心脏效应的线索？

IF 2.3 4区医学

Cardiology in Review Pub Date : 2025-11-01 Epub Date: 2024-01-08 DOI: 10.1097/CRD.0000000000000637

Patrick Savage, Lana Dixon, David Grieve, Chris Watson

{"title":"SGLT2 Inhibition in Heart Failure: Clues to Cardiac Effects?","authors":"Patrick Savage, Lana Dixon, David Grieve, Chris Watson","doi":"10.1097/CRD.0000000000000637","DOIUrl":"10.1097/CRD.0000000000000637","url":null,"abstract":"Following the publication of several landmark clinical trials such as dapagliflozin in patients with heart failure and reduced ejection fraction, dapagliflozin evaluation to improve the lives of patients with preserved ejection fraction heart failure, and empagliflozin outcome trial in patients with chronic heart failure with preserved ejection fraction, sodium-glucose cotransport 2 inhibitors have been rapidly incorporated as a guideline-directed therapy in the treatment of heart failure. Moreover, their benefits appear to extend across the spectrum of left ventricular dysfunction which in some respects, can be seen as the holy grail of heart failure pharmacotherapy. Despite its plethora of proven cardioprotective benefits, the mechanisms by which it exerts these effects remain poorly understood, however, it is clear that these extend beyond that of promotion of glycosuria and natriuresis. Several hypotheses have emerged over the years including modification of cardiovascular risk profile via weight reduction, improved glucose homeostasis, blood pressure control, and natriuretic effect; however, these mechanisms do not fully explain the potent effects of the drug demonstrated in large-scale randomized trials. Other mechanisms may be at play, specifically the down-regulation of inflammatory pathways, improved myocardial sodium homeostasis, modulation of profibrotic pathways, and activation of nutrient deprivation signaling pathways promoting autophagic flux. This review seeks to summarize the cardioprotective benefits demonstrated in major clinical trials and provide a succinct review of the current theories of mechanisms of action, based on the most recent evidence derived from both clinical and laboratory data.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"509-516"},"PeriodicalIF":2.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12498970/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139377230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Marijuana and Vascular Disease: A Review. 大麻与血管疾病：综述。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2025-11-01 Epub Date: 2024-01-08 DOI: 10.1097/CRD.0000000000000649

Ivan B Ye, George L Hines

引用次数: 0

Pharmacological Update and Emerging Treatments of Pulmonary Hypertension. 肺动脉高压的最新药理和新兴疗法。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2025-11-01 Epub Date: 2024-01-31 DOI: 10.1097/CRD.0000000000000647

Shazli Khan, Sukhbir Randhawa, Haris Patail, Yaakov Spira, William H Frishman, Wilbert S Aronow, Gregg M Lanier

{"title":"Pharmacological Update and Emerging Treatments of Pulmonary Hypertension.","authors":"Shazli Khan, Sukhbir Randhawa, Haris Patail, Yaakov Spira, William H Frishman, Wilbert S Aronow, Gregg M Lanier","doi":"10.1097/CRD.0000000000000647","DOIUrl":"10.1097/CRD.0000000000000647","url":null,"abstract":"Pulmonary hypertension (PH) is defined as elevated pressures in the pulmonary artery and is associated with significant morbidity and mortality. The World Health Organization classifies PH into 5 distinct groups based on underlying etiology, pathology, and modality of treatment. Therapeutic approach may be challenging due to the extensive spectrum of causes and underlying mechanisms mediating PH. The 5 groups include pulmonary arterial hypertension (group 1), PH secondary to left heart disease (group 2), PH secondary to chronic lung disease (group 3), chronic thromboembolic pulmonary hypertension (group 4), and PH due to miscellaneous causes (group 5). Although significant progress has been made in the treatment of group 1 PH, there is a continued need to develop new therapies for all types of PH. Additionally, most treatments currently available improve functional capacity and symptoms but without a significant benefit in mortality. In this review, we aim to describe the various etiologies of PH and their established pharmacotherapies, as well as expand on emerging therapeutic options for each group.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"494-501"},"PeriodicalIF":2.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139641662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0